Deciphera Pharmaceuticals Inc Stock News

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Margarida Duarte - SVP & Head, International Steven Hoerter - President, CEO

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the

Axsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval for its lead candidate AXS-05 by second-quarter 2022 to treat major depressive disorder.

The consensus price target hints at a 78.9% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward tre

AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.

Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.

Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022

Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.